Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?

Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • 9 hours ago

Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets

SAN FRANCISCO, Oct. 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m.

PRNewsWire • Oct 27, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 45,750 shares of its common stock and 2,775 restricted stock units (RSUs) to sixteen newly-hired employees under Nektar's 2025 Inducement Plan, as amended. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and amended on September 23, 2026 to increase the number of shares of common stock reserved and available for issuance under the plan by 250,000 shares, for a total of 500,000 shares.

PRNewsWire • Oct 23, 2026

Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?

NKTR advances rezpeg into phase III studies for atopic dermatitis, with additional autoimmune indications offering potential growth amid stiff competition.

Zacks Investment Research • Oct 15, 2026

Cedar Grove Capital Q3 2026 Portfolio Update

During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican Grill, The Ensign Group, Gemini Space Station, Jersey Mike's Subs, Moderna, Reformation, Once Upon a Farm, and X-Energy Inc. We initiated a small tracking position in Zedcor Inc. while continuing our due diligence.

Seeking Alpha • Oct 7, 2026

Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More

Nektar Therapeutics is downgraded from Strong Buy to Hold due to safety concerns with REZPEG despite positive efficacy data. Phase 2b REZOLVE-AA study showed 63% off-treatment durability but 91.7% injection site reactions, raising doubts about REZPEG's market potential in AA. NKTR maintains a strong cash position [$1.02B as of June 2026], sufficient to fund operations into Q3 2028, reducing near-term dilution risk.

Seeking Alpha • Oct 2, 2026

Nektar Therapeutics Tumbles Despite Long-Term Benefit From Alopecia Drug

Nektar Therapeutics stock took a hit Thursday despite test results that suggested its drug has long-term benefits for alopecia patients.

Investors Business Daily • Oct 1, 2026

Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial

Nektar Therapeutics NASDAQ: NKTR presented new clinical and biomarker findings for rezpegaldesleukin, or REZPEG, at the EADV 2026 Congress, highlighting six-month off-treatment results in severe to very severe alopecia areata and molecular findings from its Phase IIb atopic dermatitis program.

MarketBeat • Oct 1, 2026

Nektar Therapeutics (NKTR) Shareholder/Analyst Call Transcript

Nektar Therapeutics (NKTR) Shareholder/Analyst Call Transcript

Seeking Alpha • Oct 1, 2026

New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026

Rezpegaldesleukin demonstrated durability and deepening of response through one year of treatment in two dermatological indications, reinforcing the differentiated properties of this novel Treg mechanism In alopecia areata patients, SALT Score ≤20 response maintained in 75% at 4 months off treatment and in 63% at six months off treatment Hair regrowth continued for 6 months off treatment with 19% of patients achieving SALT Score ≤10, an improvement from 7% at the end of 52 weeks of treatment Third Phase 3 study in the global ZENITH AD program initiated, expanding the program into treatment-experienced atopic dermatitis patients; Phase 3 ZENITH AA study to initiate in early 2027 Company to host conference call with investors and analysts at 8:00 AM ET/2:00 PM CET SAN FRANCISCO and VIENNA, Oct. 1, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that long-term data on rezpegaldesleukin from the Phase 2b REZOLVE-AA and Phase 2b REZOLVE-AD studies are being presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna, Austria in two oral presentation sessions. At EADV 2026, data from the 52-week treatment extension cohort and the 6-month off-treatment period in the global Phase 2b REZOLVE-AA study in patients with severe-to-very-severe alopecia areata are being presented by Dr. David Rosmarin, Chair of Dermatology, Indiana University School of Medicine in an oral presentation entitled "Rezpegaldesleukin, a Novel Regulatory T Cell-Inducing Biologic, Demonstrates Efficacy and Safety in Severe-to-Very-Severe Alopecia Areata: 52-Week Results from the Phase 2b REZOLVE-AA Study" [link to presentation].

PRNewsWire • Oct 1, 2026